Evidence map›Paper›PMID 39474038›Full record

ArticleTurkish journal of biology = Turk biyoloji dergisi2024

Correction of Griscelli Syndrome Type 2 causing mutations in the

Özgür Doğuş Erol, Şimal Şenocak, Burcu Özçimen, Gülen Güney Esken, Hasan Basri Kiliç, Çetin Kocaefe, Niek P VAN Til, Fatima Aerts Kaya

Abstract read
In one paragraph

Article in Turkish journal of biology = Turk biyoloji dergisi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Özgür Doğuş ErolDepartment of Stem Cell Sciences, Center for Stem Cell Research and Development, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0001-9301-5401
Şimal ŞenocakDepartment of Stem Cell Sciences, Center for Stem Cell Research and Development, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-4030-4215
Burcu ÖzçimenDepartment of Stem Cell Sciences, Center for Stem Cell Research and Development, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0001-7623-8662
Gülen Güney EskenDepartment of Stem Cell Sciences, Center for Stem Cell Research and Development, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-3158-1587
Hasan Basri KiliçDepartment of Medical Biology, Faculty of Medicine, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-3204-5567
Çetin KocaefeHacettepe University Advanced Technologies Application and Research Center, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0003-3216-9399
Niek P VAN TilAmsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-9515-4103
Fatima Aerts KayaDepartment of Stem Cell Sciences, Center for Stem Cell Research and Development, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-9583-8572

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Griscelli Syndrome Type 2 (GS-2) is a rare, inherited immune deficiency caused by a mutation in the Materials and methods: We assessed Results: MSCs and iPSCs from the GS-2 patients lacked Conclusion: The use of CRISPR/Cas9 to genetically correct MSCs and iPSCs from GS-2 patients with different mutations through HDR is feasible but requires optimization of the procedure to reduce cell death and improve stem cell function before clinical application.

Indexed as

CRISPR/Cas9electroporationhomology-directed repairnonhomologous end joining

Identifiers

PMID39474038
PMCPMC11518329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.